CTAP 201

Drug Profile

CTAP 201

Alternative Names: CTAP201 Injection

Latest Information Update: 11 Feb 2016

Price : $50

At a glance

  • Originator Cytochroma
  • Developer OPKO Health
  • Class Vitamins
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Secondary hyperparathyroidism

Most Recent Events

  • 04 Mar 2013 Cytochroma has been acquired by OPKO Health
  • 10 May 2010 Safety and efficacy data from a phase I study in Secondary hyperparathyroidism were released by Cytochroma
  • 06 Jan 2009 Phase-I clinical trials in Secondary hyperparathyroidism in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top